Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Replicel Life Sciences Inc V.RP

Alternate Symbol(s):  REPCF

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair... see more

TSXV:RP - Post Discussion

Replicel Life Sciences Inc > Private Placement
View:
Post by Ingiboy on Dec 29, 2022 10:55pm

Private Placement

Dec. 30th the Private Placement closes.  It will be interesting to see if it was full subscribed.  Possibly they have been holding off updating the trip to Japan until the PP closes.
From Twitter:
"We just arrived in Japan! We are meeting with multiple potential investors and partners for all of our products: RCH-01 for regrowing hair, RCS-01 for rejuvenating skin, RCT-01 for repairing tendons,& DermaPrecise for precision injections. CEO Andrew Schutte is busy. Stay tuned."

Well we are staying tuned.......anything to report?
Comment by Ingiboy on Jan 03, 2023 9:52pm
Well, let's take a look at how this PP went.  Of the $1,050,000 value of shares offered they managed to sell $841,965.     Which Directors bought into the PP (NR Jan 3nd 2023): "Each of Andrew Schutte, Peter Lowry, Peter Lewis and Gary Boddington participated in the offering," Andrew Schutte ($400,000+) Peter Lowry Peter Lewis Gary Boddington Which Directors did ...more  
Comment by Genie29j on Jan 04, 2023 12:59am
It's clear as day now - these insiders are all buyers! Unless there was a sense of obligation or they know something we don't, either way I always prefer when the management team has skin in the game. 
Comment by lscfa on Jan 04, 2023 9:07pm
8 insiders.....   REPLICEL LIFE SCIENCES INC. ("RP") BULLETIN TYPE:  Private Placement-Non-Brokered BULLETIN DATE:  January 4, 2023 TSX Venture Tier 1 Company TSX Venture Exchange has accepted for filing documentation with respect to a Non-Brokered Private Placement announced on September 6, 2022 ...more  
Comment by bluemoons20 on Jan 05, 2023 11:13am
Too bad the market is not showing the same enthusiasm as  the long time shareholders on this board!!! GLTA
Comment by Ingiboy on Jan 05, 2023 11:53am
Unfortunately the overall market is firstly waiting for any sign that the company will produce revenue (Dermaprecise) and secondly resolve this dispute with Shiseido which both have gone on endlessly. Until that happens the share price is going nowhere.  I thought by now we would have had a quick update on the Japan trip.  Is no news good news or bad news ? 
Comment by Genie29j on Jan 05, 2023 9:56pm
The Japaninese take a lot of courting in business deals. Any new serious investor(s) could take months+  I once helped broker a partnership with a Japanese supplier for my company and it took 4 months and my leaders 3 different trips to them for dinners.  Anything is possible, but I would suspect Replicel isn't in a better position at this point. My guess is they are lining ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities